124 related articles for article (PubMed ID: 11281812)
1. Experimental approaches and drugs in development for the treatment of dementia.
Emre M; Qizilbash N
Expert Opin Investig Drugs; 2001 Apr; 10(4):607-17. PubMed ID: 11281812
[TBL] [Abstract][Full Text] [Related]
2. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease.
Castro A; Conde S; Rodriguez-Franco MI; Martinez A
Mini Rev Med Chem; 2002 Feb; 2(1):37-50. PubMed ID: 12369956
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
4. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
Doraiswamy PM
CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
[TBL] [Abstract][Full Text] [Related]
5. [Alzheimer's disease: from brain lesions to new drugs].
Forette F; Hauw JJ
Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
[TBL] [Abstract][Full Text] [Related]
6. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
Franke AG; Lieb K; Fellgiebel A
Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
[TBL] [Abstract][Full Text] [Related]
7. Memantine for dementia?
Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
[TBL] [Abstract][Full Text] [Related]
8. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
Parnetti L; Senin U; Mecocci P
Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule Natural Products and Alzheimer's Disease.
Wu X; Cai H; Pan L; Cui G; Qin F; Li Y; Cai Z
Curr Top Med Chem; 2019; 19(3):187-204. PubMed ID: 30714527
[TBL] [Abstract][Full Text] [Related]
10. [Antidementia drugs].
Müller-Spahn F; Sollberger D; Wollmer MA
Ther Umsch; 2009 Jun; 66(6):432-40. PubMed ID: 19496039
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
12. [Alzheimer's disease: therapeutic perspectives].
Dubois B; De Souza L; Allali G; Kalafat M; Sarazin M
Bull Acad Natl Med; 2008 Feb; 192(2):333-42; discussion 343-4. PubMed ID: 18819687
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
14. [New therapeutic options in Alzheimer's disease].
García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs.
Grundman M; Corey-Bloom J; Thal LJ
J Neural Transm Suppl; 1998; 53():255-75. PubMed ID: 9700663
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy against amyloid pathology in Alzheimer's disease.
Galimberti D; Ghezzi L; Scarpini E
J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
[TBL] [Abstract][Full Text] [Related]
17. Lines of therapeutics research in Alzheimer's disease.
Shvaloff A; Neuman E; Guez D
Psychopharmacol Bull; 1996; 32(3):343-52. PubMed ID: 8961777
[TBL] [Abstract][Full Text] [Related]
18. Current approaches in the treatment of Alzheimer's disease.
Shah RS; Lee HG; Xiongwei Z; Perry G; Smith MA; Castellani RJ
Biomed Pharmacother; 2008; 62(4):199-207. PubMed ID: 18407457
[TBL] [Abstract][Full Text] [Related]
19. Drugs for cognitive loss and dementia.
Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
[No Abstract] [Full Text] [Related]
20. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
Lahiri DK; Rogers JT; Greig NH; Sambamurti K
Curr Pharm Des; 2004; 10(25):3111-9. PubMed ID: 15544501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
